Alphavax, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1997-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.alphavax.com
Clinical Trials
6
Active:0
Completed:6
Trial Phases
1 Phases
Phase 1:6
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (100.0%)A Safety and Immunogenicity Trial in Adults 65 Years of Age or Over to Prevent Influenza
Phase 1
Completed
- Conditions
- Influenza
- First Posted Date
- 2008-06-30
- Last Posted Date
- 2012-07-12
- Lead Sponsor
- AlphaVax, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT00706732
- Locations
- 🇺🇸
Johnson County Clin-Trials, Lenexa, Kansas, United States
A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing Malignancies
Phase 1
Completed
- Conditions
- Colorectal CancerBreast CancerLung CancerPancreatic CancerColon Cancer
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2012-07-12
- Lead Sponsor
- AlphaVax, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT00529984
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
A Phase 1/2 Clinical Trial of an Alphavirus Replicon Vaccine for Influenza
Phase 1
Completed
- Conditions
- Influenza
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2008-11-10
- Lead Sponsor
- AlphaVax, Inc.
- Target Recruit Count
- 216
- Registration Number
- NCT00440362
- Locations
- 🇺🇸
Johnson County Clin-Trials, Lenexa, Kansas, United States
A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV)
Phase 1
Completed
- Conditions
- Cytomegalovirus Infections
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2008-11-10
- Lead Sponsor
- AlphaVax, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00439803
- Locations
- 🇺🇸
Cincinnati Center for Clinical Research, Cincinnati, Ohio, United States
Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults
Phase 1
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2004-12-01
- Last Posted Date
- 2012-07-02
- Lead Sponsor
- AlphaVax, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT00097838
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸New York Blood Center - Bronx, Bronx, New York, United States
🇺🇸New York Blood Center - Union Square, New York, New York, United States
- Prev
- 1
- 2
- Next
News
No news found